This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Alnylam Pharmaceuticals CEO Discusses Q3 2010 Results – Earnings Call Transcript

Alnylam Pharmaceuticals, Inc. ( ALNY)

Q3 2010 Results Conference Call

November 3, 2010 4:30 PM ET


Cynthia Clayton – Senior Director of IR and Corporate Communications

John Maraganore – CEO

Akshay Vaishnaw – SVP, Clinical Research

Patty Allen – VP of Finance and Treasurer

Barry Greene – President and COO


Marko Kozul – ThinkEquity

Ted Tenthoff – Piper Jaffray

Keay Nakae – Chardan Capital

Alan Carr – Needham & Company

Steven Willey – Stifel Nicolaus



Ladies and gentlemen, thank you for standing by. Welcome to the Alnylam Pharmaceuticals conference call to discuss the third quarter 2010 activities and financial results.

There will be a question-and-answer session to follow. Please be advised that this call is being taped at the company’s request.

I’d now like to hand the call over to Alnylam.

Cynthia Clayton

Good afternoon. I’m Cynthia Clayton, Senior Director of Investor Relations and Corporate Communications at Alnylam. With me today are John Maraganore, our Chief Executive Officer; Barry Greene, our President and Chief Operating Officer; Akshay Vaishnaw, Senior Vice President, Clinical Research; and Patty Allen, Vice President of Finance and Treasurer. In addition, Laurence Reid, our Chief Business Officer is also on the call and available for Q&A.

For those of you participating via conference call, the slides we have made available via webcast can also be accessed by going to the Investors page of our website,

During today’s call, as outlined on Slide 2, John will provide some introductory remarks and general context, Akshay will summarize our clinical and preclinical R&D activities, Patty will review our financials and guidance, and Barry will summarize our business highlights and goals. We will then open the call for your questions.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.33 -2.30%
FB $99.20 -10.00%
GOOG $666.59 -5.90%
TSLA $152.45 -13.00%
YHOO $27.36 -6.10%


Chart of I:DJI
DOW 15,973.08 -231.89 -1.43%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs